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Abstract
Background: Serum cystatin C (s-CC), an endogenous marker of kidney function, has also been proposed as a 
cardiovascular risk marker. However, it is unknown whether it is a direct marker of atherosclerosis, independently of 
kidney function.
Objective: The aim of this study was to correlate s-CC with two surrogate markers of subclinical atherosclerosis.
Methods: This is a cross-sectional study involving 103 middle-aged (57.49 ± 11.7 years) hypertensive outpatients, being 
60 female (58.25%), most with preserved kidney function. S-CC was correlated with carotid intima media thickness 
(IMT) and flow-mediated dilation of brachial artery (FMD), both assessed by ultrasound, as well as with measured 
creatinine clearance and established cardiovascular risk factors.
Results: S-CC was neither significantly correlated with IMT (r = –0.024; p = 0.84) nor with FMD (r = –0.050; p = 0.687) 
and no significant association was observed with conventional risk factors and inflammatory markers. In univariate 
analysis, s-CC was correlated with measured creatinine clearance (r = -0,498; p < 0,001), age (r = 0,408; p < 0,001), 
microalbuminuria (r = 0,291; p = 0,014), uric acid (r = 0,391; p < 0,001), ratio E/e’ (r = 0,242; p = 0,049) and 
Framingham score (r = 0,359; p = 0,001). However, after multiple regression analysis, only the association with 
measured creatinine clearance remained significant (r = -0,491; p < 0,001).
Conclusion: In middle-aged hypertensive outpatients, s-CC correlated with measured creatinine clearance, as expected, 
but no association was observed with markers of atherosclerosis neither with established cardiovascular risk factors. 
(Arq Bras Cardiol 2012;99(4):899-906)
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Introduction
Cystatin C, a novel endogenous marker of kidney function, 
has been proposed also as a marker of cardiovascular risk1. 
It is a member of the superfamily of cysteine proteinase 
inhibitors produced by all nucleated cells. Because of its low 
molecular weight, it is freely filtered by the glomeruli and 
almost completely reabsorbed and catabolized in the tubules, 
without suffering tubular secretion, characteristics that make 
it more sensitive and accurate than creatinine2.
Many studies have demonstrated association between 
this serum protein and various established cardiovascular 
risk factors and markers1,3-9, incidence of coronary events10,11 
and heart failure12,13 and, more importantly, the risk of 
cardiovascular death, particularly in the elderly14-16.
Some authors have argued that, as cystatin C is involved in 
the protein catabolism, inhibiting elastolitic proteases, which 
are augmented in degenerative and inflammatory processes 
like atherosclerosis, it could function as a direct marker of the 
atherogenic process itself1,10,17.
However, at the present time, it is not established whether 
s-CC is merely a better marker of kidney function, which 
would be truly implicated in the cardiovascular risk, or if 
it could be considered a direct marker of atherosclerosis, 
independent of kidney function18.
Therefore, this study aimed to correlate s-CC levels in 
hypertensive patients without overt cardiovascular disease 
with two surrogate markers of subclinical atherosclerosis at the 
same time, namely the carotid intima media thickness (IMT) 
and the flow-mediated dilation of brachial artery (FMD), as 
well as with traditional risk factors and inflammatory markers.
Methods
This is a cross-sectional study involving hypertensive 
outpatients attended at a university service, chosen at random. 
We considered exclusion criteria for the enrollment in the 
research: a history of thyroid disease and/or current use of 
thyroxine, macroproteinuria (≥ 300 mg/ 24h), current use 
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as an increase in left ventricular mass index ≥ 115 g/m² 
for men and > 95 g/m² for women22. The left ventricular 
ejection fraction was estimated by Teichholz’s method and 
was used as the parameter of left ventricular systolic function22. 
Left ventricular diastolic function was assessed by the ratio E/e’ 
(the early diastolic transmitral flow velocity divided by the early 
diastolic mitral annular velocity obtained from tissue Doppler), 
which has been used to estimate left ventricular filling pressure23.
A 7.5-MHz linear array transducer, with a frequency 
range of 7-10 MHz, was used to measure common carotid 
IMT. Thickness measurement was performed at the posterior 
artery wall, 1 cm proximal to carotid bifurcation, as the 
distance between two echogenic lines corresponding to the 
lumen-intima and media-adventitia interfaces of the artery 
wall, according to current recommendations24. It was 
considered normal a carotid IMT ≤ 1mm.
A 10- MHz linear array transducer was used to assess the 
FMD of the brachial artery, according to technique published 
previously25. After assessment of baseline diameter of the right 
brachial artery (D1), a cuff was inflated to 50 mm Hg above the 
participant’s systolic blood pressure to occlude the artery and 
kept inflated for 5 minutes. Images of the right brachial artery 
were then obtained 60-90 seconds after cuff deflation and 
artery diameter was measured again (D2), in diastole (gated 
with ECG R wave). %FMD was computed with the formula 
D2-D1/D1 x 100 and adopted as an estimation of endothelial 
function. Acceptable normal values vary from 10 to 15%25.
Association between s-CC levels (mg/L), used as a 
continuous or as a categorical variable (< or ≥ 50th 
percentile), and  each of the following variables was searched: 
age (years), smoking (yes/no), diabetes mellitus (yes/no), 
sedentary lifestyle (yes/no), waist circumference (cm), body 
mass index (kg/m2), systolic and diastolic blood pressure 
(mmHg), total cholesterol (mg/dL), HDL-cholesterol (mg/dL), 
LDL-cholesterol (mg/dL), triglycerides (mg/dL), glucose (mg/dL), 
glycosylated hemoglobin (%), urea (mg/dL), creatinine (mg/dL), 
measured creatinine clearance (ml/min/1.73m2), estimated 
creatinine clearance by Cockcroft-Gault and MDRD formulas 
(ml/min/1.73m2), uric acid (mg/dL), microalbuminuria 
(mg/24h), high sensitivity C-reactive protein (mg/dL), 
fibrinogen (mg/dL), left ventricular ejection fraction (%), ratio 
E/e’, left ventricular mass index (g/m2), FMD (%), carotid IMT 
(mm), Framingham score (%) and metabolic syndrome (yes/no). 
The project was previously approved by the Institution’s 
Research Ethics Committee. Informed consent was obtained 
from all participants.
Categorical variables were expressed as percentage (%) and 
continuous variables, as mean ± standard deviation (SD). To 
compare means it was used the Student’s t-test and categorical 
variables, the chi-square test (χ2). Pearson’s correlation 
coefficient, or Spearman’s coefficient for nonparametric 
variables, was calculated to analyze the association between 
two continuous variables, being adopted a 95 % confidence 
interval. All statistical analysis were conducted using the 
SPSS package for Windows, version 16.0. Two-tailed 
p values < 0,05 were considered as expressing a statistically 
significant association. Associations presenting a p < 0.10 
at the univariate analysis were included in the final multiple 
regression analysis model.
of anti-inflammatory agents or high sensitivity C-reactive 
protein > 10 mg/l and a history and/ or clinical evidence of 
atherosclerotic disease.
All participants underwent a structured medical history 
interview, including the search for cardiovascular risk factors, 
and physical examination, which included measure of waist 
circumference, height and weight. Body mass index was 
calculated as weight in kilograms divided by the square of 
height in meters (Kg/m2). Blood pressure was defined as the 
average of the last two of three measurements with a mercury 
sphygmomanometer taken at intervals ≥ 2 minutes after the 
participants had been seated for at least 5 minutes. Smoking 
was defined as current smoking of ≥ 1 cigarette/ day. Those 
participants who reported to practice < 30 minutes three 
times/ week of physical exercise were considered sedentary.
Fasting (12-hour) venous samples were drawn and 
biochemical parameters were assayed using an automatic 
analyzer. The following measurements were obtained: glucose, 
urea, creatinine, potassium, total cholesterol, HDL-cholesterol, 
LDL-cholesterol, triglycerides, leukocyte count, uric acid, 
high sensitivity C-reactive protein, fibrinogen and s-CC. Each 
participant collected his or her own urine for 24 h for the 
determination of microalbuminuria and creatinine clearance. 
High sensitivity C-reactive protein and microalbuminuria 
were measured by immunoturbidimetry. Measured creatinine 
clearance was standardized by the body surface area and was 
used as an index of glomerular filtration rate, being considered 
low when < 60 ml/min/1.73m2. Creatinine clearance was 
also estimated by Cockcroft-Gault and Modification in Diet 
in Renal Disease (MDRD) formulas19. S-CC was measured by 
a particle-enhanced immunonephelometric assay (N Latex 
Cystatin C, Dade Behring) with a nephelometer (BNII). The 
range of detection of the assay is 0,195 to 7,330 mg per liter, 
with the reference range for healthy persons reported as 0,53 
to 0,95 mg per liter14.
Diabetes mellitus was defined as fasting plasma glucose 
≥ 126 mg/dL, using any hypoglycaemic medication and/ 
or a 2h glucose ≥ 200 mg/dL in an oral glucose tolerance 
test. Dyslipidemia was defined as elevated total cholesterol 
(≥ 200 mg/dL), decreased HDL-cholesterol (< 40 mg/dl in 
males and < 50 mg/dL in females), elevated LDL-cholesterol 
(≥ 160mg/dL), elevated triglycerides (≥ 150 mg/dL) and/or 
using hypolipemiant agents20. 
The individual’s absolute 10-year risk of coronary 
heart disease was estimated by means of the Framingham 
score20. Metabolic syndrome was identified according to the 
International Diabetes Federation criteria21. 
All participants underwent transthoracic echocardiography, 
measurement of carotid IMT and assessment of FMD of 
the brachial artery with high-resolution Doppler B-mode 
ultrasound equipment (General Electric). Examinations were 
performed by two experts operators, blinded to the patient’s 
clinical and laboratory findings.
Echocardiography was performed using a 3,5 MHz 
transducer. Left ventricular mass (g) was estimated using the 
formula of Devereux and Reichek and the left ventricular mass 
index was calculated by dividing left ventricular mass by body 
surface area (g/m2). Left ventricular hypertrophy was defined 
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Results 
One hundred and three hypertensive outpatients were 
recruited for this research, with a mean age of 57.49 ± 
11.7 years and predominance of female and non-whites. 
The sample was characterized also by an average measured 
creatinine clearance within normal range and a glomerular 
filtration rate < 60 ml/min/1.73 m² in less than 1/5 of the 
participants. Clinical and laboratory data of the study sample 
are shown in Table 1.
With respect to risk assessment, it was observed a mean 
Famingham score of 9.0 ± 8.4%, being 58.9% of the 
participants classified as low, 25% as medium and 16% as high 
risk. Mean s-CC was 0.75 ± 0.16 mg/L, following a normal 
distribution, being significantly higher in male (0.80 ± 0.15 vs. 
0.72 ± 0.16 mg/L, p = 0.039), with no difference between 
whites and non-whites (0.78 ± 0.16 vs. 0.73 ± 0.15 mg/L, 
p = 0.15). It was observed a significant correlation with age 
(r = 0.408, p < 0.001) and a trend in relation to body mass 
index (r = -0.193, p = 0.091).
As can be seen in Table 2, s-CC was significantly 
correlated with all other kidney function parameters. The 
inverse correlation observed between s-CC and measured 
creatinine clearance, considered to be the reference marker 
of glomerular filtration rate in this study, remained significant 
even after adjustment for age (r = -0.369, p=0.001), gender 
(r = -0.412, p < 0.001), race (r = -0.419, p < 0.001), body 
mass index (r = -0.383, p = 0.001) and all these variables 
jointly (r = -0.365, p = 0.002). As shown in Table 3, all other 
estimated kidney function parameters except urea were also 
significantly correlated with measured creatinine clearance.
No significant association was observed between s-CC 
levels and diabetes mellitus (p = 0.915), smoking (p = 0.881), 
sedentary lifestyle (p = 0.115), dyslipidemia (p = 0.865) and 
metabolic syndrome (p = 0.526). 
A strong inverse correlation between the two subclinical 
atherosclerosis markers evaluated in this work, namely carotid 
IMT and FMD of brachial artery, was observed (r = -0.480, 
p < 0.001). However, as shown in Table 4, s-CC was not 
significantly correlated with any of these markers. In the 
same way, there was no correlation with the inflammatory 
markers studied here, namely leukocyte count, high sensitivity 
C-reactive protein and fibrinogen. On the other hand, s-CC 
correlated significantly with microalbuminuria, uric acid, ratio 
E/e’ and Framingham score.
However, after multiple linear regression analysis including 
all associations with p < 0.10, only the correlation with 
measured creatinine clearance remained significant, being 
observed a borderline significance for the association with 
uric acid (Table 5).
Discussion
In the current study we evaluated hypertensive outpatients 
free of manifested cardiovascular disease, predominantly of 
middle age, with preserved renal function and classified as of 
low and medium risk according to Famingham score. These 
characteristics correspond to a profile of patient commonly 
found in the daily clinical practice, for which there is yet 
uncertainty about risk assessment.
As expected, s-CC correlated significantly with all 
kidney function parameters evaluated, including measured 
creatinine clearance. Taking measured creatinine clearance 
as a reference, s-CC performance was roughly equivalent to 
Cockcroft-Gault formula. However, as creatinine clearance, 
even measured, cannot be considered a gold standard of 
kidney function, it is possible that s-CC sensitivity is being 
underestimated in this analysis.
In this research, s-CC was not significantly correlated 
with markers of atherosclerosis, inflammatory markers, left 
ventricular mass index, neither with traditional risk factors 
Table 1 – Baseline characteristics of study population (n= 103)
Age, mean (± SD), years 57.49 (11.7)
Woman, n (%) 60 (58.2)
Non-white, n (%) 66 (64.1)
Cigarette smoking, n (%) 10 (9.8)
Physically inactive, n (%) 44 (42.7)
Diabetes mellitus, n (%) 17 (16.5)
Family history of premature coronary heart disease, n (%) 50 (48.5)
Body mass index, mean (± SD), Kg/m² 28.0 (5.0)
Waist circumference, mean (± SD), cm 
    Men 92.9 (9.6)
    Woman 92.5 (10.0)
Metabolic syndrome, n (%) 53 (51.5)
Dyslipidemia, n (%) 75 (72.8)
Systolic blood pressure, mean (± SD), mmHg 145.9 (21.7)
Diastolic blood pressure, mean (± SD), mmHg 87.0 (12.7)
Antihypertensive agents use, n (%) 100 (97.0)
Total cholesterol, mean (± SD), mg/dL 206.0 (44.3)
HDL-cholesterol, mean (± SD), mg/dL
    Men 42.5 (9.3)
    Woman 48.9 (11.8)
LDL-cholesterol, mean (± SD), mg/dL 132.8 (38.3)
Triglyceride, mean (± SD), mg/dL 153.05 (66.0)
Creatinine, mean (± SD), mg/dL 0.84 (0.22)
Creatinine clearance, mean (± SD), ml/min/1.73 m²
    Measured 94.8 (43.3)
    Estimated by Crockcroft-Gault formula 88.36 (30.28)
    Estimated by MDRD formula 95.5 (26.25)
Measured creatinine clearance < 60 ml/min/1,73 m², n (%) 19 (18.4)
Glucose, mean (± SD), mg/dL 103.15 (26.0)
Urea, mean (± SD), mg/dL 30.25 (9.4)
Carotid IMT, mean (± SD), mm 1.06 (0.22)
High carotid IMT, n (%) 46 (44.6)
Left ventricular mass index, mean (± SD), g/m² 103.55 (26.17)
Left ventricular hypertrophy, n (%) 52 (50.48)
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except age. On the other hand, the significant associations 
observed with uric acid, microalbuminuria, ratio E/e’ and 
Framingham score, as well as with age, disappeared after 
multiple regression analysis, remaining significant only the 
correlation with measured creatinine clearance.
Carotid IMT and FMD of brachial artery have been 
considered as, respectively, structural and functional markers 
of subclinical atherosclerosis26-29. As expected, in the current 
study, a strong inverse linear correlation between these two 
markers was observed, corroborating the fact that they reflect 
different aspects of the same pathophysiologic process. The few 
studies that aimed to correlate s-CC with these markers have 
reported conflicting findings. While two small cross-sectional 
studies involving middle-aged hypertensive patients reported 
significant correlation between s-CC and carotid IMT3,30, larger 
cross-sectional studies did not confirm it, neither in middle-aged 
individuals, with preserved kidney function4,31, nor in the elderly, 
with discrete to moderate kidney function impairment32. The 
Australian study conducted by Potter et al.33 was the only one, 
before ours, to correlate s-CC with either IMT as FMD at the 
same time. Indeed, it is a cross-sectional analysis of a subgroup 
of elderly stroke participants (n = 173) of the Vitamins to 
Prevent Stroke Trial (VITATOPS trial), whose primary objective 
was to evaluate the effectiveness of homocysteine lowering with 
B-vitamins supplementation in the reduction of incidence of 
major vascular events. The authors observed no correlation with 
IMT; with regard to FMD, they found a significant correlation, 
but clearly influenced by kidney function.
In short, our findings corroborate the role of s-CC as marker of 
kidney function but do not demonstrate independent association 
with markers of atherosclerosis neither with established risk 
factors. Therefore, based on our findings, as well as others’, 
we believe that the widely reported association between s-CC 
and cardiovascular risk is fundamentally connected to its role as 
kidney function marker and reject in principle the hypothesis 
that it could reflect independently an intrinsic vascular damage 
and consequently the atherogenic process itself.
Among other authors, the postulated role of s-CC as 
a marker of inflammation and atherosclerosis has been 
controversial too. Despite innumerous publications reporting 
significant association between s-CC and various inflammatory 
markers1,5-8,10,14,34-36, it is not established yet if this association is 
independent of kidney function. Singh et al.36 for instance, in 
a cross-sectional analysis of the elderly cohort Heart and Soul 
Study, verified that the significant correlation observed among 
s-CC and high sensitivity C-reactive protein and fibrinogen 
simply disappeared after adjustment for measured creatinine 
clearance. If one considers that renal impairment itself, even 
slight, is associated to inflammatory markers elevation, s-CC 
could simply reflect, with more sensitivity than creatinine or 
estimated creatinine clearance, this association. 
With respect to its association with markers of atherosclerosis, 
beyond the divergent findings regarding carotid IMT and FMD, 
including ours, it must be added the absence of significant 
association with coronary calcification evaluated by computed 
tomography, as demonstrated in a cross-sectional analysis of 
the large Multi-Ethnic Study of Atherosclerosis (MESA)6. In the 
same way, a significant correlation with microalbuminuria was 
reported by some authors3,4,8, but not by other7.
In the European cohort Prospective Epidemiological 
Study of Myocardial Infarction (PRIME Study), that included 
only healthy middle-aged men, s-CC was significantly 
associated with the occurrence of the first coronary event, 
independently of classical factors, but the significance of this 
association disappeared after adjusting for high sensitivity 
C-reactive protein35.
Table 2 – Univariate correlation between s-CC and conventional kidney function parameters
Variable r value p value
Urea 0.507 < 0.001
Creatinine 0.515 < 0.001
Measured creatinine clearance - 0.498 < 0.001
Estimated creatinine clearance by:
Cockcroft-Gault formula - 0.518 < 0.001
MDRD formula - 0.520 < 0.001
Table 3 - Correlation between the different estimated kidney function parameters and measured creatinine clearance
Variable r value p value
Cystatin C - 0.498 < 0.001
Urea - 0.111 0.304
Creatinine - 0.388 < 0.001
Cockcroft-Gault formula 0.487 < 0.001
MDRD formula 0.385 < 0.001
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In a recently published cohort, theTromsø Study,  which 
studied a general population, involving more than 6.000 
adult men and women, cystatin C was a risk factor for 
all-cause mortality in women but was not independently 
associated with fatal and non-fatal myocardial infarction or 
ischemic stroke in the whole population.37 Even in the large 
elderly cohorts, in which s-CC presented strong correlation 
with cardiovascular mortality, its association specifically with 
atherosclerotic events, namely acute myocardial infarction 
and stroke, did not become defined, being demonstrated in 
the Cardiovascular Health Study14,  but not in the Health ABC 
study15. The Health ABC’s authors speculate that individuals 
with renal impairment, even slight or moderate, may have 
a disproportionally higher risk of fatal events rather than 
nonfatal acute myocardial infarction or stroke. This could be 
due to the greater incidence of ventricular arrhythmias and 
sudden death in this setting, not necessarily associated to 
atherosclerotic events, once these individuals have a greater 
prevalence of structural abnormalities of the conduction 
system, myocardial fibrosis and hypertrophy, ventricular 
Table 4 – Univariate correlation between s- CC and different clinical and laboratory continuous variables evaluated 
Variable r value p value
Systolic blood pressure 0.211 0.064
Diastolic blood pressure 0.086 0.455
Waist circumference - 0.052 0.655
Glucose - 0.026 0.817
Glycosylated hemoglobin 0.071 0.552
Microalbuminuria 0.291 0.014
Uric acid 0.391 < 0.001
Potassium 0.095 0.446
Leukocyte count 0.047 0.685
High sensitivity C- reactive protein - 0.139 0.228
Fibrinogen 0.123 0.339
Total cholesterol total 0.008 0.945
HDL- cholesterol 0.040 0.729
LDL- cholesterol - 0.087 0.462
Triglycerides 0.152 0.184
Left ventricular mass index 0.026 0.824
Ratio E/e’ 0.242 0.049
Left ventricle ejection fraction 0.003 0.981
Carotid IMT - 0.024 0.844
FMD of brachial artery - 0.050 0.687
Framingham score 0.359 0.001
Table 5 – Results of multiple linear regression including all associations with p < 0,10 
Variable β value p value
Measured creatinine clearance - 0.491 < 0.001
Uric acid 0.229 0.059
Age 0.111 0.377
Microalbuminuria - 0.115 0.343
Rate E/e’ 0.066 0.594
Framingham score 0.002 0.990
Body mass index - 0.032 0.805
Systolic blood pressure 0.029 0.811
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dysfunction and heart failure15. So, the apparent superiority 
of s-CC over creatinine based kidney function assessment, 
regarding cardiovascular risk prediction, as showed in these 
cohorts, could be fundamentally due to its greater sensitivity 
to detect smaller degrees of renal impairment, which would 
be the true cardiovascular risk predictor. In accordance with 
this, in patients with advanced chronic kidney disease, Menon 
et al.38 demonstrated that the strength of s-CC regarding 
cardiovascular risk prediction was not clearly superior to that 
of measured glomerular filtration rate with iothalamate. 
On the other hand, it is possible that in the setting of 
myocardial injury, in which there is intense extracellular matrix 
remodeling, s-CC levels keep correlation with the extension of the 
injury and, consequently, with the future risk of cardiac events. 
It is why in this particular situation there is a great augmentation 
of elastolytic proteases, which can be counterbalanced for 
elevation of its main inhibitor, cystatin C. This could likely explain 
the predictive capacity of s-CC, regarding secondary cardiac 
events, independent of kidney function, as demonstrated by 
Koenig et al.10 in patients with recent acute coronary syndrome, 
most with acute myocardial infarction, as well as its absence in 
the setting of chronic stable coronary heart disease as reported 
by the Heart and Soul Study39. The same explanation could 
be proposed for the association between s-CC and the risk of 
development of heart failure, a condition characterized also by 
intense extracellular matrix remodeling40.
As said before, the role of s-CC as an independent marker 
of atherosclerosis seems to be not yet established, a point of 
view that has been endorsed by some of the main researchers 
in this area1,39. So we believe that renal impairment, even slight, 
is the true cardiovascular risk predictor, and s-CC, just a more 
sensitive marker of this impairment. 
Finally, the present study was limited by its cross-
sectional design. Furthermore, as our study evaluated a 
specific profile of patients, our results cannot automatically 
be extrapolated to the general population. On the other 
hand, our work presents some positive aspects that should 
be emphasized. To our knowledge, it is the first study 
to correlate s-CC with these two markers of subclinical 
atherosclerosis, at the same time, in individuals without 
manifested cardiovascular disease. Furthermore, we also 
correlated s-CC with inflammatory markers, 24-hour 
microalbuminuria and left ventricular mass index, beyond 
traditional risk factors, as well as we worked with measured 
rather than estimated creatinine clearance. 
Conclusion
In middle-aged hypertensive outpatients, most with 
preserved kidney function, s-CC correlated with measured 
creatinine clearance, as expected, but no association was 
observed with two markers of atherosclerosis neither with 
established cardiovascular risk factors. 
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